Form 4: Arcturus CEO Granted 175,000 Stock Options

Arcturus Therapeutics Holdings Inc. CEO Joseph E. Payne was granted 175,000 employee stock options with an exercise price of $6.52, vesting over four years.

Summary

• Joseph E. Payne, President and CEO, and a Director of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 175,000 employee stock options.
• The options have an exercise price of $6.52 per share.
• The grant date for these options was December 17, 2025.
• The options vest 25% on December 17, 2026, which is the first anniversary of the grant date.
• The remaining options will vest in equal monthly increments over the subsequent thirty-six months.
• The expiration date for these stock options is December 17, 2035.
• The options were granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
• Following this transaction, Joseph E. Payne beneficially owns 175,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is a routine compensation event that aligns management's interests with shareholders, generally viewed as a neutral to slightly positive development for corporate governance and long-term strategy.

Positives

• The grant of stock options to the President and CEO aligns management's interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The long vesting schedule (four years) encourages long-term commitment and performance from the executive.

Future Outlook

The filing details a compensation grant with a vesting schedule extending over the next four years, indicating a long-term incentive structure for the CEO. No other forward-looking statements or guidance are provided.

Industry Context

Executive stock option grants are a common form of compensation in the biotechnology and pharmaceutical industries, aiming to incentivize leadership through equity participation and align their financial interests with long-term company growth and shareholder value creation. The exercise price of $6.52 reflects the stock price at the time of the grant.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, vary significantly across the biotechnology industry based on company size, stage of development, performance, and specific executive roles. Without detailed compensation benchmarks for comparable companies (e.g., Moderna, BioNTech, Alnylam Pharmaceuticals) at a similar stage and market capitalization, a direct assessment of this specific grant's size relative to industry standards is not feasible from this filing alone.
• The four-year vesting schedule is a common practice for executive equity grants, designed to promote long-term retention and performance.

Corporate Governance

Related Party Transactions

• The reported grant of 175,000 employee stock options to Joseph E. Payne, the President and CEO, constitutes a related party transaction as it involves compensation between the company and a key executive.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's financial incentives with shareholder value creation, as the options gain value if the stock price increases. Dilution from future exercise of options is a potential, though common, consideration.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The options will begin vesting on December 17, 2026, with subsequent monthly vesting increments for the following 36 months.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Joseph Payne, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan